Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

Mansoor, Saffar; Kuppermann, Baruch D.; Kenney, M. Cristina

doi:10.1007/s11095-008-9812-z

Cited by 60 publications

(36 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When a drug needs to be released from a reservoir in the active device, a voltage is applied, which causes electrochemical dissolution of the gold anode membrane. Active systems include mechanical pumping, electrolysis and other actuation methods (Mansoor et al, 2009;Choonara et al, 2010;Eljarrat-Binstock et al, 2010). In contrast, the passive polymeric device contains biodegradable polymer membranes.…”

Section: Theory Of Operationmentioning

confidence: 99%

Implantable microchip: the futuristic controlled drug delivery system

2014

View full text Add to dashboard Cite

There is no doubt that controlled and pulsatile drug delivery system is an important challenge in medicine over the conventional drug delivery system in case of therapeutic efficacy. However, the conventional drug delivery systems often offer a limited by their inability to drug delivery which consists of systemic toxicity, narrow therapeutic window, complex dosing schedule for long term treatment etc. Therefore, there has been a search for the drug delivery system that exhibit broad enhancing activity for more drugs with less complication. More recently, some elegant study has noted that, a new type of micro-electrochemical system or MEMS-based drug delivery systems called microchip has been improved to overcome the problems related to conventional drug delivery. Moreover, micro-fabrication technology has enabled to develop the implantable controlled released microchip devices with improved drug administration and patient compliance. In this article, we have presented an overview of the investigations on the feasibility and application of microchip as an advanced drug delivery system. Commercial manufacturing materials and methods, related other research works and current advancement of the microchips for controlled drug delivery have also been summarized.

show abstract

Section: Theory Of Operationmentioning

confidence: 99%

Implantable microchip: the futuristic controlled drug delivery system

2014

View full text Add to dashboard Cite

show abstract

“…Additionally, the non-biodegradable polymer implants have no initial adverse burst of the drug, which is superior to other types of devices (Yasukawa et al, 2005). However, the non-biodegradable polymers are not metabolized or degraded in the body, and therefore, the empty device must be removed by a second surgery, which exposes the patient to potential complications (Mansoor et al, 2009). On the other hand, biodegradable implantable devices are composed of synthetic or natural biomaterials, which degrade into nontoxic byproducts by enzymatic or nonenzymatic hydrolysis or solubilize in vivo and can be eliminated safely by the human body (Lee et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of methotrexate-loaded poly(ε-caprolactone) implants in Ehrlich solid tumor-bearing mice

Pereira

Barbosa

et al. 2013

Drug Delivery

View full text Add to dashboard Cite

Context: Methotrexate (MTX) is used in the treatment of malignancies; however, its clinical application is limited by its toxic dose-related side effects. An alternative to overcome the toxicity of the MTX in healthy tissues is the design of an implantable device capable of controlling the delivery of this drug for an extended period within the tumor site. Objective: To develop methotrexate-loaded poly("-caprolactone) implants (MTX PCL implants) and to demonstrate their efficacy as local drug delivery systems capable of inhibiting Ehrlich solid tumor bearing mice. Materials and methods: MTX PCL implants were produced by the melt-molding technique and were characterized by FTIR, WAXS, DSC and SEM. The in vitro and in vivo release of MTX from the PCL implants was also evaluated. The efficacy of implants in inhibiting tumor cells in culture and the solid tumor in a murine model was revealed. Results and discussion: The chemical and morphological integrity of the drug was preserved into the polymeric matrix. The in vitro and in vivo release processes of the MTX from the PCL implants were modulated by diffusion. MTX diffused from the implants revealed an antiproliferative effect on tumor cells. Finally, MTX controlled and sustained released from the polymeric implants efficiently reduced 42.7% of the solid tumor in mice paw. Conclusion: These implantable devices represented a contribution to improve the efficacy and safety of chemotherapy treatments, promoting long-term local drug accumulation in the targeted site.

show abstract

“…Both degradable and nondegradable polymers have been studied for injectable systems for ocular delivery. 70 Non-degradable polymers such as poly(ethylene-covinyl acetate) exhibit long term, constant rates of delivery for a number of drugs; 71 however, their disadvantage is the continued presence of a foreign body with a resulting immune response. Degradable polymers such as poly(lactic acid) or poly(lactic-co-glycolic acid) are an appealing alternative.…”

Section: Injectable Systemsmentioning

confidence: 99%

Novel drug delivery systems for glaucoma

Lavik

Kuehn

Kwon

2011

Eye

139

View full text Add to dashboard Cite

Reduction of intraocular pressure (IOP) by pharmaceutical or surgical means has long been the standard treatment for glaucoma. A number of excellent drugs are available that are effective in reducing IOP. These drugs are typically applied as eye drops. However, patient adherence can be poor, thus reducing the clinical efficacy of the drugs. Several novel delivery systems designed to address the issue of adherence and to ensure consistent reduction of IOP are currently under development. These delivery systems include contact lensesreleasing glaucoma medications, injectables such as biodegradable micro-and nanoparticles, and surgically implanted systems. These new technologies are aimed at increasing clinical efficacy by offering multiple delivery options and are capable of managing IOP for several months. There is also a desire to have complementary neuroprotective approaches for those who continue to show progression, despite IOP reduction. Many potential neuroprotective agents are not suitable for traditional oral or drop formulations. Their potential is dependent on developing suitable delivery systems that can provide the drugs in a sustained, local manner to the retina and optic nerve. Drug delivery systems have the potential to improve patient adherence, reduce side effects, increase efficacy, and ultimately, preserve sight for glaucoma patients. In this review, we discuss benefits and limitations of the current systems of delivery and application, as well as those on the horizon.

show abstract

Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

Cited by 60 publications

References 87 publications

Implantable microchip: the futuristic controlled drug delivery system

Implantable microchip: the futuristic controlled drug delivery system

Efficacy of methotrexate-loaded poly(ε-caprolactone) implants in Ehrlich solid tumor-bearing mice

Novel drug delivery systems for glaucoma

Contact Info

Product

Resources

About